GlassScriptPhysician profile
Kamran A Torbati
NPI 1639183056
$8,487.52
in general payments reported to CMS, 2019-2025
27 companies · $4,680 in 2025
The $4,680 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $808 · 2021: $468 · 2022: $399 · 2023: $292 · 2024: $1,291 · 2025: $4,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,400 · Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,400.00 |
| Food and Beverage | $863.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $5,400.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $735.92 | 2019-2023 | Orilissa, Lo Loestrin Fe, Qulipta |
| Therapeuticsmd, INC. | $328.96 | 2019-2022 | |
| Celularity INC. | $300.00 | 2020 | |
| Hologic Sales and Service, LLC | $236.05 | 2021-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Pfizer INC. | $198.63 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $186.12 | 2021-2025 | |
| Avion Pharmaceuticals | $174.21 | 2019-2022 | |
| Coopersurgical, INC. | $132.41 | 2020-2025 | Paragard T 380a |
| Organon LLC | $121.95 | 2024 | |
| Merck Sharp & Dohme LLC | $92.77 | 2024-2025 | Gardasil 9, Gardasil |
| Sage Therapeutics, LLC | $55.75 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $55.35 | 2020-2025 | |
| Allergan, INC. | $51.79 | 2019 | |
| Sumitomo Pharma America, INC. | $50.91 | 2025 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $50.46 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $47.12 | 2019 | |
| Scynexis, INC. | $41.81 | 2022 | |
| Exeltis, USA INC. | $41.21 | 2019 | |
| Roche Diagnostics Corporation | $33.82 | 2019 | |
| Shield Therapeutics INC | $29.39 | 2023 | Accrufer |
| Vertical Pharmaceuticals, LLC | $24.64 | 2019 | |
| Millicent US INC | $23.55 | 2025 | Femlyv, Intrarosa |
| Agile Therapeutics, INC. | $22.33 | 2023 | Twirla |
| Astellas Pharma US INC | $19.39 | 2022 | |
| Myovant Sciences INC. | $18.45 | 2021 | |
| Evofem Biosciences, INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Torbati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.